Organogenesis (NASDAQ: ORGO) CFO uses share dispositions to cover taxes

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported four tax-withholding dispositions of Class A common stock on February 15, 2026, at $3.73 per share. After these transactions related to tax obligations, he directly owned 506,647 Class A shares.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Francisco David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Class A Common Stock	3,898	$3.73	$15K
Tax Withholding	Class A Common Stock	21,412	$3.73	$80K
Tax Withholding	Class A Common Stock	13,369	$3.73	$50K
Tax Withholding	Class A Common Stock	13,769	$3.73	$51K

Holdings After Transaction: Class A Common Stock — 555,197 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francisco David

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/15/2026		F		3,898	D	$3.73	555,197	D
Class A Common Stock	02/15/2026		F		21,412	D	$3.73	533,785	D
Class A Common Stock	02/15/2026		F		13,369	D	$3.73	520,416	D
Class A Common Stock	02/15/2026		F		13,769	D	$3.73	506,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stacie S. Aarestad, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Organogenesis (ORGO) report for its CFO?

Organogenesis reported that CFO Francisco David completed four tax-withholding dispositions of Class A common stock on February 15, 2026, using existing shares to satisfy tax obligations rather than executing open-market sales.

How many Organogenesis (ORGO) shares were used for the CFO’s tax withholding?

CFO Francisco David disposed of blocks of 3,898, 21,412, 13,369, and 13,769 Class A shares at $3.73 per share, all coded as F transactions for tax-withholding purposes.

What does transaction code F mean in the Organogenesis (ORGO) Form 4?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. For Organogenesis, CFO Francisco David used Class A shares to cover tax obligations instead of conducting traditional market sales.

How many Organogenesis (ORGO) shares does the CFO own after these transactions?

After the reported dispositions, CFO Francisco David directly owned 506,647 shares of Organogenesis Class A common stock, as disclosed in the Form 4 following the final tax-withholding transaction on February 15, 2026.

Were the Organogenesis (ORGO) CFO’s Form 4 transactions open-market sales?

The transactions were coded F and described as tax-withholding dispositions, meaning shares were delivered to satisfy tax obligations. They were not classified as open-market buys or sells in the Form 4 data.

What price per share was used in the Organogenesis (ORGO) CFO’s Form 4 entries?

Each reported tax-withholding disposition by CFO Francisco David used a transaction price of $3.73 per Class A common share, as disclosed for all four Form 4 entries dated February 15, 2026.